{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:59:36Z","timestamp":1776099576604,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lung cancer incidence is increasing worldwide. Despite being cornerstone treatment modalities, both chemotherapy and targeted therapy are accompanied by treatment-related toxicities. The aim of this study is to identify key authors, leading countries, core journals, and keywords in research on treatment-related toxicities of tyrosine kinase inhibitors (TKIs) used for non-small-cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A literature search was conducted in the Web of Science Core Collection database on June 28, 2025. The search strategy used the terms \u201cnon-small cell lung cancer,\u201d \u201ctoxicity,\u201d and \u201ctyrosine kinase inhibitors,\u201d and their combination with Boolean operators (AND, OR, NOT). Bibliometric analyzes were conducted using the Bibliometrix R-package along with the Biblioshiny interface for visualization and data exploration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 366 publications on TKIs in NSCLC were identified between 2009 and 2025. Annual scientific production increased from 2 to 56 publications, with an average annual growth rate of 20%. China led with 580 papers, followed by Japan (381) and the United States (358). Harvard University ranked first among institutions (n\u2005=\u200546), followed by its medical affiliates, Pfizer, and the University of California System. The most productive journal was\n                      <jats:italic toggle=\"yes\">Lung Cancer<\/jats:italic>\n                      (n\u2005=\u200518), whereas the\n                      <jats:italic toggle=\"yes\">Journal of Clinical Oncology<\/jats:italic>\n                      had the highest impact factor (IF\u2005=\u200541.9). The most cited publication was Peters et al, which received 1830 citations, while average citation per article is 23. Analysis of author keywords revealed 3 major thematic clusters, encompassing strategies to overcome resistance, approaches to manage TKI-related toxicities, and studies on specific molecular subtypes (anaplastic lymphoma kinase, epidermal growth factor receptor). The most prevalent keywords were \u201cnon-small cell lung cancer\u201d (32%) and \u201cosimertinib\u201d (23%), reflecting the central focus on third-generation TKIs in current research.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Optimizing NSCLC therapy with TKIs requires proactive toxicity monitoring and integration of predictive biomarkers and real-world evidence to enhance efficacy and patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047860","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:00:30Z","timestamp":1772240430000},"page":"e47860","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tyrosine kinase inhibitor toxicity in the treatment of non-small-cell lung cancer: A bibliometric analysis (2009\u20132025)"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0430-1807","authenticated-orcid":false,"given":"Lazzat","family":"Balymbetova","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yerbolat Maratovich","family":"Iztleuov","sequence":"additional","affiliation":[{"name":"Department of Radiology, Marat Ospanov West Kazakhstan Medical University, Aktobe, Republic of Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnara Kereevna","family":"Ismagulova","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarkyt","family":"Kozhantayeva","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aigerim","family":"Balapasheva","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, \u0421linical Pharmacology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2174\/0929867323666160405111152","article-title":"Advances in nanocarriers for anticancer drugs delivery.","volume":"23","author":"Ali","year":"2016","journal-title":"Curr Med Chem"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN.","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"R5-20260413","first-page":"6","article-title":"Social aspects of cancer genesis.","volume":"8","author":"Ali","year":"2011","journal-title":"Cancer Ther"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.21037\/tlcr-20-382","article-title":"Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study.","volume":"9","author":"Xu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12885-024-11956-w","article-title":"The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.","volume":"24","author":"Cheng","year":"2024","journal-title":"BMC Cancer"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020).","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4143\/crt.2022.1438","article-title":"EGFR-TKI combined with pemetrexed versus EGFR-TKI monotherapy in advanced EGFR-mutated NSCLC: a prospective, randomized, exploratory study.","volume":"55","author":"Gu","year":"2023","journal-title":"Cancer Res Treat"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"1285280","DOI":"10.3389\/fonc.2024.1285280","article-title":"Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors.","volume":"14","author":"Halmos","year":"2024","journal-title":"Front Oncol"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"e38277","DOI":"10.1097\/MD.0000000000038277","article-title":"Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials.","volume":"103","author":"Lai","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/polym12030598","article-title":"Progress in polymeric nano-medicines for theranostic cancer treatment.","volume":"12","author":"Ali","year":"2020","journal-title":"Polymers (Basel)"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/antiox13121578","article-title":"Cisplatin-induced hearing loss, oxidative stress, and antioxidants as a therapeutic strategy\u2014a state-of-the-art review.","volume":"13","author":"Rose","year":"2024","journal-title":"Antioxidants"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11523-024-01073-w","article-title":"Adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer: an updated meta-analysis.","volume":"19","author":"Zhou","year":"2024","journal-title":"Target Oncol"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3892\/ol.2022.13649","article-title":"Side effects of tyrosine kinase inhibitors therapy in patients with non\u2011small cell lung cancer and associations with EGFR polymorphisms: a systematic review and meta\u2011analysis.","volume":"25","author":"Obradovic","year":"2023","journal-title":"Oncol Lett"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"e36010","DOI":"10.1097\/MD.0000000000036010","article-title":"Sensorineural hearing loss induced by gefitinib: a CARE-compliant case report and literature reviews.","volume":"102","author":"Zhu","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2147\/DDDT.S510031","article-title":"Research trends of tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a bibliometric analysis.","volume":"19","author":"Chang","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.2147\/DDDT.S478910","article-title":"Deciphering the dynamics of EGFR-TKI resistance in lung cancer: insights from bibliometric analysis.","volume":"18","author":"Zhou","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK -positive non-small-cell lung cancer.","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"R22-20260413","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"R23-20260413","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"R24-20260413","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study.","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol"},{"key":"R25-20260413","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"key":"R26-20260413","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","article-title":"Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.","volume":"28","author":"Sequist","year":"2010","journal-title":"J Clin Oncol"},{"key":"R27-20260413","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.21037\/jtd-24-682","article-title":"Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer.","volume":"16","author":"Li","year":"2024","journal-title":"J Thorac Dis"},{"key":"R28-20260413","doi-asserted-by":"crossref","first-page":"1652750","DOI":"10.3389\/fphar.2025.1652750","article-title":"Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study.","volume":"16","author":"Miao","year":"2025","journal-title":"Front Pharmacol"},{"key":"R29-20260413","doi-asserted-by":"crossref","first-page":"1380453","DOI":"10.3389\/fonc.2024.1380453","article-title":"Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis.","volume":"14","author":"O\u2019Reilly","year":"2024","journal-title":"Front Oncol"},{"key":"R30-20260413","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14796694.2024.2370239","article-title":"Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysis.","volume":"21","author":"Cai","year":"2024","journal-title":"Futur Oncol"},{"key":"R31-20260413","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1038\/d41586-025-01154-4","article-title":"China overtakes the United States in cancer research output.","volume":"640","author":"Wilson","year":"2025","journal-title":"Nature"},{"key":"R32-20260413","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/acsptsci.0c00167","article-title":"Rising academic contributions to drug development: evidence of vigor or trauma?","volume":"3","author":"Kinch","year":"2020","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:01:00Z","timestamp":1776096060000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047860","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}